The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database
Authors:
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Current Problems in Cancer
- Vol. 44 (6) , 100613
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Systemic therapy for pulmonary carcinoidsLung Cancer, 2015
- Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?Clinical Cancer Research, 2015
- Incidence of Second Primary Malignancies in Patients with Neuroendocrine TumoursNeuroendocrinology, 2015
- Secondary malignancy in patients with sporadic neuroendocrine neoplasiaEndocrine, 2013
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnnals of Oncology, 2012
- Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreasEndocrine-Related Cancer, 2011
- Large-Cell Neuroendocrine Carcinoma of the Lung HarboringEGFRMutation and Responding to GefitinibJournal of Clinical Oncology, 2011
- Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE TrialJournal of Clinical Oncology, 2011
- Treatment options for small cell lung cancer – do we have more choice?British Journal of Cancer, 2010
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008